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Abstract. The leukocyte ß1 integrin receptor very late
activation antigen-4 (VLA-4) (cY4ßi, CD49d/CD29)
binds to vascular cell adhesion molecule-1 (VCAM-1)
expressed on cytokine-activated endothelium. A mAb
designated 8A2 was identified that stimulated the bind-
ing of U937 cells to CHO cells transfected with
VCAM-1 cDNA but not endothelial-leukocyte adhesion
molecule or CD4 cDNA. mAb 8A2 also rapidly stim-
ulated the adherence of peripheral blood lymphocytes
(PBLs) to VCAM-1-transfected CHO cells or recom-
binant human tumor necrosis factor-treated human
umbilical vein endothelial cells. mAb 8A2-stimulated
binding of PBL was inhibited by mAbs to VLA-4 or
VCAM-1. Surface expression of VLA-4 was not altered
T
HE emigration of lymphocytes to extravascular sites
ofinflammation or immune reaction is mediated by the
interaction ofadhesive surface proteins or lymphocytes
with ligands on endothelial cells and matrix components.
The binding of lymphocyte function-associated antigen-1
(LFA-1), to intercellular adhesion molecule-1 (ICAM-1) and
very late activation antigen-4 (VLA-4) with vascular cell ad-
hesion molecule-1 (VCAM-1, inducible cell adhesion mole-
cule-110 [INCAM-110]) accounts for a major component of
lymphocyte binding to cytokine-activated cultured endothe-
lium (7, 16, 32, 34). LFA-1 (CDlla/CD18) is an integrin re-
ceptor of the 01 subfamily that interacts with the endothe-
lial cell ligands ICAM-1(CD54) or ICAM-2, closely related
members of the immunoglobulin superfamily (25, 40, 43,
44) . VLA-4 (CD49d/CD29) is an integrin receptor of the
ß, subfamily that has recently been shown to bind to both
the CS-1 fragment of fibronectin (18, 50) andto vascular cell
adhesion molecule-1 (VCAM-1) (12), a cytokine-induced en-
dothelial protein of the immunoglobulin superfamily (28).
1 . Abbreviations used in this paper: SLAM-1, endothelial leukocyte adhe-
sion molecule-1; HUVE, human umbilical vein endothelial cell; ICAM-1,
intercellular adhesion molecule-1 ; LFA, lymphocyte function-associated
antigen 1 ; NCS, normal calf serum; PBL, peripheral blood lymphocyte;
TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule-1 ;
VLA, very late activation antigen.
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by mAb 8A2 treatment and monovalent Fab fragments
of mAb 8A2 were active. Immunoprecipitation studies
reveal that mAb 8A2 recognizes ß1-subunit (CD29) of
integrin receptors. In contrast to mAbs directed to
VLA-4 alpha-subunit (tx4, CD49d), mAb 8A2 did not
induce homotypic aggregation of PBL. Additionally,
mAb 8A2 stimulated adherence of PBL and hemato-
poietic cell lines to purified matrix components lami-
nin and fibronectin . This binding was blocked by
mAbs to the VLA alpha-subunts a6 (CD49f), or «5
(CD49e) and a4 (CD49d), respectively. We conclude
that mAb 8A2 modulates the affinity of VLA-4 and
other leukocyte ß, integrins, and should prove useful
in studying the regulation of ß, integrin function.
Migration of peripheral blood lymphocyte (PBL) through
the subendothelial matrix is dependent at least in part upon
other VLA antigens including VLA-5 (CD49e/CD29) and
VLA-4 binding to fibronectin and VLA-6 (CD49f/CD29) to
laminin (reviewed in 37) .
The adhesive interactions of these receptors and ligands
can be regulated at the level of the leukocyte or the endo-
thelial cell. Expression of endothelial cell ICAM-1 is in-
creased by interferon-gamma, lipopolysaccharide, interleu-
kin-1, tumor necrosis factor (TNF) (11, 30), or phorbol
esters (23), while VCAM-1 is induced by IL-1, TNF, lipo-
polysaccharide and interleukin-4 (7, 16, 26, 28, 32, 46). In
the case of LFA-1, activation by phorbol ester treatment or
cross-linking of T-cell receptor, CD2, or CD3 increases the
binding of LFA-1 to ICAM-1 (10, 48) . Phorbol esters also in-
crease the avidity of ß, integrins (4, 38, 39, 45, 51) .
We now describe a mAb, 8A2, that is directed to an epi-
tope on 01 (CD29) . mAb 8A2 rapidly induces enhanced
binding of PBLs to cytokine-activated human umbilical en-
dothelial cells (HUVEs) . Stimulation of PBL adherence to
HUVE by mAb 8A2 is dose dependent, requires energy, and
is mediated primarily by binding of VLA-4 to VCAM-1.
mAb 8A2 also stimulates binding of lymphocytes and hema-
topoietic cell lines to purified fibronectin via VLA-4 or
VLA-5 and to purified laminin via VLA-6.
499Materials andMethods
Cell Culture
HUVEs were harvested by collagenase treatment ofumbilical cord veins as
previously described (31) . Cells were grown and maintained in RPMI 1640
medium (M . A . Bioproducts, Walkersville, MD) supplemented with 10%
adult bovine serum (Hyclone Sterile Systems, Logan, UT), 10% normal
calf serum (Armour Pharmaceutical Co., Kanakee, IL), heparin 90 ug/ml
(Sigma Chemical Co ., St . Louis, MO), (47), and endothelial cell growth
factor (50 F+g/ml) prepared from bovine hypothalamus (24) .
CHO cells stably transfected and expressing endothelial leukocyte adhe-
sion molecule-1 (ELAM-1), VCAM-1, ICAM-1, and CD4 were the gift of
Drs. Roy Lobb, Barbara Wallner, and Margaret Rosa, Biogen, Inc . (Cam-
bridge, MA) . Cells were grown and maintained in MEM-alpha medium
without ribonucleosides or deoxyribonucleosides (Gibco Laboratories,
Grand Island, NY), supplemented with 10% FBS (Hyclone Sterile Systems,
Logan, UT), and 4 mM glutamine (Gibco Laboratories) . Methotrexate
(SigmaChemical Co., St. Louis, MO), 200mM, was added to themedium
for the VCAM-1, ELAM-1, and ICAM-1 cells, while the CD4 transfectants
were grown in the presence of 30 mM methotrexate .
Suspension cultures of the myelomonocytic cell line U937 (ATCC,
Walkersville, MD), lymphoid cell lines Molt-4 and Ramos (ATCC), and
erythroleukemic cell line K562 (ATCC) were maintained in MEM (M.A .
Bioproducts) supplemented with 10% FBS. The lymphoblastoid cell line,
JY, was a gift of Dr. Roy Lobb, Biogen, Inc . (Cambridge, MA), and was
maintained in RPMI 1640 medium with 10% FBS.
The murine nonsecretory myeloma cell line, NS-1, was the gift of Dr.
Charles Hart, Zymogenetics (Seattle, WA) . The myeloma cells and subse-
quent hybridomas were maintained inRPMI 1640 supplemented with 15 %
heat-inactivated FBS, 4 mM glutamine, 0.1 mM nonessential amino acids
(Gibco Laboratories), 1 mM sodium pyruvate (Gibco Laboratories) and
0.075% sodium bicarbonate (Gibco Laboratories) .
The melanoma cell line, 2669, was thegift ofDr. Karl E . Hellstrom, On-
cogene (Seattle, WA) . The melanoma cells were maintained in Earles
ModifiedEagles Medium (M.A . Bioproducts) and supplemented with 10%
FBS (Hyclone Sterile Systems), 2 mM glutamine (Gibco Laboratories), 1
mM sodiumpyruvate (Gibco Laboratories) and 0.1mM nonessential amino
acids (Gibco Laboratories) .
Antibodies and Reagents
Murine mAb 60 .3 which recognizes the 02 subunit (CD18) of the
CDll/CD18 complex (1) was the gift of Dr. Patrick Beatty, Fred Hutchinson
Cancer Research Center (Seattle, WA) . Murine mAb 4B9 whichrecognizes
VCAM-1 was generated as previously described (7) . The a4 (CD49d)mAb
163H wasthe gift ofDr. Michael Gallatin, ICOS Corporation (Seattle, WA)
and the a4 (CD49d) mAbs HP 1/l, HP 1/2 andHP 2/1 were the gifts of Dr.
Francisco Sanchez-Madrid, Service Immunologia, Hospital de lao Prin-
cesa, (Madrid, Spain) (33) . The rat a6 (CD49f) mAb GoH3 was the gift
of Drs . Taco Kuijpers and Arnoud Sonnenberg, Central Laboratory ofthe
Netherlands Red Cross Blood Transfusion Service (Amsterdam, The
Netherlands) (41, 42) . The anti-ELAM-1 mAb BBII was the gift of Drs.
Roy Lobb and Christopher Benjamin, Biogen, Inc . (Cambridge, MA) (3) .
The 01 (CD29) murine mAb P4C10, the 012 (CD49b) mAb P4B4, and a3
(CD49c)mAb PIB4 were the gifts ofDr. ElizabethWayner, Cytel Corpora-
tion (La Jolla, CA) (8) . MurinemAb 4B4 directed to 01 (CD29) was pur-
chased from CoulterCorp. (Hialeah, FL) . Polyclonal antibody A108 which
recognizes the VLA-5 fibronectin receptor (a581, CD49e/CD29) and mu-
rine monoclonal PID6 which recognizes a5 (CD49e) were purchased from
Telios Pharmaceuticals, Inc . (San Diego, CA).
Recombinant human TNF-alpha (rhTNF) was the gift of Dr . Roy Lobb,
Biogen Corp . (Cambridge, MA) . Sodium azide, 2-mercapto-ethanol and
glutaraldehyde were purchased from Eastman Kodak Co. (Rochester, NY) .
Hydrogen peroxide, o-phenylenediamine, NP-40, PMSF, glucose, and
2-deoxyglucose were purchased from Sigma Chemical Co. (St . Louis, MO) .
Leukocytes
Blood was obtained by venipuncture from normal healthy donors under ap-
proved protocol . Blood was drawn into polypropylene syringes containing
heparin 10 U/ml. The blood was centrifugated over Ficoll-Hypaque (Phar-
macia Fine Chemicals, Piscataway, NJ) at 500 g for 40 min at 24°C. The
mononuclear layer at the plasma-Ficoll interface was collected by aspira-
tion. Monocytes were removed by two cycles ofadherenceto serum-coated
tissueculturepetri dishes (Becton Dickinson&Co ., LincolnPark, NJ) . The
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suspension of nonadherent cells containing primarily lymphocytes was cen-
trifuged for 6 min at 500 g, resuspended in RPMI 1640 medium with 2%
bovine serum (Gibco Laboratories) for use in the adherence assays .
Polymorphonuclear leukocytes were isolated from the Ficoll-RBC inter-
face of the above preparationby 3% dextran sedimentation and lysis of con-
taminating red blood cells by hypotonic saline .
Matrix-coated Plates
Purified human fibronectin and murine laminin were purchased from Col-
laborative Research, Inc. (Bedford, MA) . The matrix components were
resuspended in PBS at 15 14g/ml . 200 pl/well were added to 48-well non-
treated styrene plates (Costar Corp ., Cambridge, MA) and incubated over-
night at 4°C. Wells were rinsed once with PBS, and then incubated for 2 h
at roomtemperature with 0.5 ml ofPBS/3 % BSA to block nonspecific bind-
ing . Immediately before use, wells were rinsed three times with PBS and
0.2 ml of RPMI containing 5% normal calf serum (Gibco Laboratories)
was added .
AdherenceAssay
First- or second-passage HUVEs were plated onto gelatin-coated 48-well
tissue culture plates (Costar Corp.) and grown to confluency. Designated
wells werepretreated for 4 h at 37'C with rhTNF 10ng/ml . CHO celltrans-
fectants were plated in untreated 48-well tissue culture plates and grown to
confluency. Wells were washed once with control medium, RPMI-5 % nor-
mal calf serum (NCS) (Gibco Laboratories), and then 0.2 ml of control
medium with or without various mAbs was added for 30 min at 37°C. Pe-
ripheral blood lymphocytes, U937 and K562 cells were isolated as previ-
ously described, suspended in 0.5 ml RPMI, and labeled with 51Cr for 1 h
at 37°C. Cells were washed twice with RPMI medium containing 5% NCS
and resuspended in RPMI medium containing 5 % NCS at a concentration
of 1 x 10 6 cells/ml . Labeled cells were aliquoted and treated with mAb
8A2 at various concentrations for 30 min at 37°C. Labeled cells (0.2 ml/
well) were then added to the wells containing monolayers of HUVE or
CHO, or matrix components and incubated for 30 min at 37°C. Nonadher-
entcellswere aspirated from each well and thewells were washedonce with
0.5 ml/well PBS with2 % NCS and aspirated dry Adherent cells were lysed
with 0.5 ml/well of 1N NH40H, and the lysates were counted in a Micro-
Medic GammaCounter (Chicago, IL) for 1 min. Percentadherence wascal-
culated as :
Generation ofmAb 842
BALB/c mice were immunized with hematopoietic cell line U937. Hybrid-
omas were produced by fusion ofimmunized mouse splenocytes with NS-1
cell line using standard techniques (15) and grown in 96-well tissue culture
plates (Costar Corp .) . Hybridoma supernatants were screenedby standard
enzyme-linked immunoassay (7) for binding to the 2669 melanoma cells,
known to express VLA-4 andto bindto VCAM-1 (N . Kovach and J. Harlan,
unpublished observation) . Positive hybridomas were then evaluated for
effects on adherence of U937 cells to VCAM-1-transfected CHO cells. A
hybridoma designated 8A2 was identified by stimulation rather than inhibi-
tion of adherence of U937 cells to VCAM-1-transfected CHO cells. It was
then serially cloned three times by the method of limiting dilution. mAb
SA2 was determined to be IgG1-kappa isotype using a mouse mAb isotyp-
ing kit (Amersham Corp., Arlington Heights, IL) .
Ascites was produced by standard technique (21) . Briefly, BALB/c mice
were primed with 0.5 ml ofpristane (2, 6, 10, 14-tetramethyl-pentadecane ;
Sigma Chemical Co .) intraperitoneally 1 wk before intraperitoneal injec-
tion of 3 x 106 8A2 hybridoma cells . Ascites was collected after 2-3 wk
when significant accumulation was present.mAb 8A2 was purified from as-
cites by binding to immobilized proteinA (Pharmacia Fine Chemicals) as
previously described (13) .
Monovalent Fab fragments were generated by incubationofpurifiedmAb
8A2 with papain immobilized on sepharose bead (Pierce Chemical Co.,
Rockford, IL) for 5 h . Immobilized papain was removed by centrifugation,
and the supernatant passed aver an immobilized protein A column . The
nonbinding fraction was subjected to 7% SDS-PAGE under nonreducing
conditions to confirm purity of the preparation.
Radioimmunoprecipitation
U937 and K562 cells were surface-labeled with 125 1 as previously de-
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51CR cpm total addedscribed (20). Briefly, 15 mlpolypropylene tubes (Becton-Dickinson) were
coated with 500 Rg of Iodogen iodination reagent (Pierce Chemical Co.),
dried under a stream of nitrogen, and stored dessicated until used. Tubes
were rinsed with sample buffer at time of use, and 5 x 101 cells were
added with 1 mCi of Na1251, and incubated 20 min at room temperature.
Cells were washed three times with PBS, and then lysed for 3 h at 4aC in
PBS containing 0.5% NP-40 and 2 mM PMSF Debris and unlysed cells
were removed by centrifugation at 12,000 g for 15 min. Cell lysates were
precleared by incubationfor 1 h with 50 pg nonimmune mouse IgG (Cappel
Research Products, Organon Tecknika Corp., West Chester, PA) and 50 Al
ofrabbit serum, and subsequent incubation with Pansorbin, a 10% suspen-
sion of SACI cells coated with protein A (Calbiochem Corp., San Diego,
CA). Lysates were then cleared by centrifugation. After preclearance, ali-
quots of U937 lysate were incubated for 1 h with 10 iAg mAb 8A2, mAb
P4C10, mAb 4B4, polyclonal antibody A108, or mAb 60.3. Aliquots of la-
beled precleared K562 lysate were incubated with 10 ug mAb P4C10, mAb
PID6, mAb 8A2, or polyclonal A108. Antibody-antigen complexes were re-
moved from the lysates by incubation with 50 Al protein G immobilized to
Sepharose beads (Gamma Bind Plus; Genex Corp., Gaitherburg, MD). Im-
mobilized protein G-antibody-protein complexes wereremoved by centrifu-
gation at20,000 g for 15 min. The beadswere washedthree times with 0.1%
NP-40 in PBS, and boiled in SDS-PAGE sample buffer for 10 min.
Sepharose beads were pelletedby centrifugation and aliquots ofsupernatant
treated with 5% mercaptoethanol. Immunodepletion was accomplished by
three sequential precipitations ofthe lysates with designated antibodies. Fi-
nal precipitation of the immunodepleted lysate with mAbs P4C10, 8A2 or
60.3 was performed as described. Samples were then analyzed by 7% SDS-
PAGE and autoradiography.
Fluorescence-activated CellSorting
PBLs and neutrophils were isolated as described above. Aliquots of U937,
Molt-4, Ramos, and JY were prepared from suspension cultures in ex-
ponential growth. Leukocytes, 1 x 106 total per tube, were placed in 5-ml
polypropylene tubes (Becton-Dickinson), centrifuged 400 g for 6 min,
washed once with HBSS (Gibco Laboratories) and kept at 4aC for all
manipulations. 50 pl heat-inactivated adult bovine serum (Hyclone Sterile
Systems) was addedper tubefor 20 mintoreduce nonspecific binding. Cells
were washed once with HBSS, 50 pl of the first mAb was added at final
concentration of 1:50 for purified mAb and 1:5 for hybridoma supernatants,
and the mixture was incubated for 30 min. In the same experiments, aliquots
of U937 cells werepretreated for 30 min at 37'C with 1 /cg/ml of mAb 8A2
Fab fragments and washed twice with HBSS at 4°C before addition of first
intactmAb. After reaction with the first mAb, cells were washed three times
with cold HBSS, and 50 kl of 1:25 dilution FITC-labeled goat antimouse
Fc-specific second antibody (Tago Corp., Burlingame, CA) was added. In
the case of the rat mAb GoH3 (a6, CD49f), FITC-labeled goat anti-rat
IgG was utilized as second antibody (Organon Teknika, Corp., West
Chester, PA). After incubation for 30 min, cells were washed twice with
cold HBSS, and fixed with 250 pl of 1% paraformaldehyde. Samples were
analyzed on an Epics Cytofluorimeter (Coulter Corp., Hialeah, FL).
AggregationAssay
50 pl of PBL or U937 cell suspensions, 2 x 106 cells/ml, were pipetted
per well of a round-bottomed 96-well plate (Costar). 50 pl of the a4
(CD49d) mAbs HPl/1, HP2/2, or HP2/1 cell supernatants at 1:100 dilution
were added to designated wells. 50-,ul dilutions of purified mAb 8A2 in
RPMI with 2% NCS were added to designated wells with final concentra-
tions ranging from 1 to 1,000 ng/ml. Plates were incubated in 5 % C02 at
37°C for up to 18 h, andthen visually scored for thepresence ofaggregation
under an inverted microscope.
Results
mAb 842Stimulates U937Bindingto
VCAM1-transfected CHO Cells
mAb 8A2 was identifiedby stimulation of U937 cell binding
to VCAM-1-transfected but not CD4- or ICAM-1-transfected
CHO cells (Fig. 1) . mAb 8A2 induced a fourfold increase in
binding of U937 to VCAM-1-transfected CHO cells, and this
binding was inhibitedby the antiVCAM4 mAb 4B9 (Fig. 1).
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40 Figure 1. mAb 8A2 induces
bindingofU937 cells to WAM-
1-transfected CHO cells. "Cr-
labeled U937 cells were pre-
treated for 30 min with medium
alone or medium containing
MAb 8A2 (1 Ag/ml), and then
added to confluent monolayets
ofCD4-, ELAM-1-, or VCAM-
1-transfected CHO cells.
VCAM-1 transfectants were
pretreated for 30 min with
medium alone or medium con
taining 5 ug/ml of the antiVCAM-1 mAb 4B9. Percent adherence
was determined after a 30-min incubation at 37'C. Values are the
means f SEM of three experiments.
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mAb 842 Stimulates PBL Binding to VCAM-1
We next examined the effect of mAb ßA2 on adherence of
PBL. Treatment of PBL with mAb 8A2 induced binding to
the VCAM-1-transfected CHO cells, but not to ELAM-1- or
C134-transfectants (Fig. 2). The mAb 8A2-induced binding
to PBL to VCAM-1 was inhibited by pretreatment of the
transfectant with antiVCAM-1 mAb 4B9 or pretreatment of
PBLs with the 014 (CD49d) mAb 163H (Fig. 2). Impor-
tantly, monovalent Fab fragments of mAb 8A2 were as active
as intact IgG in stimulating PBL binding to VCAM-1 trans-
fectants (Fig. 3).
mAb 842-inducedBindingIs Energy Dependent
Sodium azide, NaN3, binds tightly to cytochrome oxidase
complex and blocks electron transport. 2-deoxyglucose
(2-DOG), is a competitive inhibitor of glucose metabolism.
The combination of 2-DOG and NaN3 abolishes energy-
dependent functions. Pretreatment of PBL with 2-DOG/
NaN3 inhibited basal binding of PBL to VCAM-1 transfec-
tants, and abolished binding induced by mAb 8A2 (Table I).
The inhibition of binding was partially reversed by addition
of glucose to compete against the 2-DOG.
Actinomycin D, a potent inhibitor of RNA synthesis,
slightly diminished binding of untreated PBLs to VCAM-1
transfectants, but had no effect on the mAb 8A2-stimulated
increase in binding (Table I).
mAb 842Stimulates PBL Binding toHUVE via
VLA-41VCAM1
mAb 8A2 stimulated adherence of PBL to untreated and
rhTNF-treated HUVE in a dose-dependent manner in the
presence of the 02 (CD18) mAb 60.3 (Fig. 4). A significant
increase in adherence was observed at -50 ng/ml, with max-
imal stimulation of adherence at 5 p,g/ml. Dose-response
curves were essentially parallel between untreated and
rhTNF-treated HUVE, but with significantly greater binding
to rhTNF-treated HUVE. Enhancement of binding occurred
rapidly. Addition of mAb 8A2 to PBL at the beginning ofthe
30-min adherence assay resulted in maximal stimulation of
adherence with no further enhancement when PBLs were
pretreated with mAb 8A2 for up to 6 h (data not shown) . All
studies were subsequently performed with a 30-min coincu-
bation of PBL and mAb 8A2 during the adherence assay.
Since PBL adherence to HUVE involves interaction of30t
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Figure2. mAb 8A2 induces binding ofPBL to VCAM-1-transfected
CHO cells. 5'Cr-labeled PBLs were pretreated with mAb 8A2
(5 ug/ml) in the presence of the 02 (CD18) mAb 60.3 (20 jAg/ml)
for 30min at 37°C. An aliquot ofPBL was also treated with 5 ug/ml
of the a4 (CD49d) mAb 163H. Confluent monolayers of CHO
cells transfected with CD4, ELAM-1, or VCAM-1 were washed and
pretreated with control medium with and without the anti-ELAM-1
mAb BBI1 (51g/ml) or the antiVCAM-1 mAb 4B9 (5 Ag/ird) for
30 min. 5'Cr-labeled PBLs were added and percent adherence was
determined aftera 30-min incubation at 37°C. Values are means t
SEM of three experiments.
LFA1 (CDlla/CD18) with ICAM-1 or ICAM-2 (25, 40, 43,
44), and VLA-4 with VCAM-1(12, 34), we utilized blocking
mAbs to these receptors and ligands to determine the effect
of mAb 8A2 on PBL binding to HUVE . Results ofthree sep-
arate experiments are summarized in Table II. Pretreatment
of HUVE with rhTNF for 4 h before addition of PBL
significantly increased the adherence of PBL compared to
untreated HUVE. The adherence of PBL to untreated and
cytokine-activated HUVE was reduced by the 02 (CD18)
mAb 60.3. Adherence to rhTNF-treated HUVE, however,
was significantly greater than adherence to untreated HUVE
even in the presence of 02 (CD18) mAb 60.3. This en-
Figure 3. Monovalent Fab frag-
ments of mAb 8A2 stimulate
PBL adherence to VCAM-1
transfectants. Monovalent FAB
fragments of mAb 8A2 were
generated by papain digestion
and affinity chromatography
as described in Materials and
Methods. 5'Cr-labeled PBL
were pretreated for 30 min
with the 02 (CD18) mAb 60.3
mAb BA2 (,AM)
￿
(20 1.g/ml) and varying con-
centrations of intact mAb 8A2
or Fab fragments. 5,Cr-labeled PBL were added to confluent
VCAM-1-transfected CHO cellsand percent adherence was deter-
mined following a 30-min incubation at 37°C. Concentration of
monovalent Fab fragments and intact mAb are expressed as mi-
crometers for direct comparison. Values are meansoffour replicate
wellsin one representative experiment offour separate experiments.
hanced binding of PBL to rhTNF-activated HUVE in the
presence of 02 (CD18) mAb 60.3 has previously been
shown to be due primarily to induction of VCAM-1 on
HUVE which interacts with VLA-4 on PBL (7, 12, 16, 32,
34) . In the presence of the CD18 mAb, the a4 (CD49d)
mAb 163H inhibited PBL binding to unstimulated and
rhTNF-stimulated HUVE.
mAb 8A2 enhanced adherence of PBL to unstimulated
HUVE and slightly to rhTNF-stimulated HUVE. The mAb
8A2-induced adherence to unstimulated HUVE and rhTNF-
stimulated HUVE was reduced by the 02 (CD18) mAb 60.3,
but the CD18-independent binding was significantly greater in
the presence of mAb 8A2 . The addition of the 04 (CD49d)
mAb 163H together with the 02 (CD18) mAb 60.3 reduced
mAb 8A2-stimulated binding to unstimulated HUVE and
rhTNF-stimulated HUVE to values not significantly different
from those observed in the absence of mAb 8A2 .
mAb 842 Stimulates Binding by an Effect on PBL
Not HUVE
Since HUVEs express the antigen recognized by mAb 8A2
Table L Metabolic Inhibitors Prevent MAb 8A2-stimulated
Binding ofPBL to VCAM-1-transfected CHO Cells
mAb 8A2-stimulated binding of PBl to VCAM-1-transfected CHO cells is in-
hibited by metabolic inhibitors. "Cr-labeled PBL were incubated in medium
alone, medium containing 2-deoxyglucose (5 mM) and NaN3 (0.1 °h) with or
without 5 mM glucose, or actinomycin D (1 Wg/ml) for 30 min at 37°C. Cells
were washed once and treated with mAb 8A2 (1 hg/ml) for 30 min and then
added to confluent VCAM-1-transfected CHO cells. Percent adherence was
determined following a 30-min incubation at 37°C. Values are the means
t SEM of quadruplicate wells in a representative experiment of four separate
experiments.
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treated 2.1 ± 1.3 4.1 t 3 .5
2-DOG/NaN3-
treated with
glucose 5 .0 t 3.9 18.6 f 5 .8
Actinomycin D 12.0 f 4.4 21 .0 t 0.8Figure 4 . mAb 8A2 induces
adherence ofPBLto HUVE .
"Cr-labeled PBL were pre-
treated with varying concen-
trations of mAb 8A2 for 30
min at 37'C in the presence of
02 (CD18) mAb 60.3 (20 jug/
MI) . 5'Cr-labeled PBLs were
then added to confluentmono-
layers of unstimulated HUVE
or HUVE pretreated with
rhTNF (10 ng/ml) for 4 h at
37°C . Percent adherence was
determined aftera30-min incubation at 37°C. Values are themeans
t SEM of triplicate wells in one representative experiment offour
separate experiments .
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(data notshown), we determined whether the effect ofmAb
8A2was on thePBL or HUVE . Pretreatment ofHUVE with
mAb 8A2 followed by washing was without effect on adher-
ence ofPBL in the presence of 02 (CD18) rnAb 60.3 (6.7 f
TableH. mAb8A2 StimulatesPBL Binding to Untreated
and rhTNF-treatedHUVE via VLA-41VCAM-1
mAb 8A2-stimulated PBL binding to untreated and rhTNF-treated HUVE is in-
hibited by blocking mAb to a4 subunit (CD49d) . HUVEs were pretreated
with medium alone or medium containing rhTNF 10 ng/ml for4 h at 37°C .
"Cr-labeled PBLs were incubated in medium alone, medium containing the
02 (CDl8) mAb 60 .3 (20 wg/ml), the a4 (CD49d) mAb 163H (10 Ag/ml), or
in combination. Aliquots of the treated PBLs were treated with mAb SA2
(1 Pg/ml) for 30 min and then added to the HUVE cell monolayers . Percent
adherence was determined following a 30-min incubation at 37°C . Values are
the means f SEM of triplicate wells in three separate experiments.
* Denotes statistically significant difference between untreated and mAb
8A2-treated binding in means by nest (P< 0.05) .
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Irrelevant IgG
rnAb 8A2 Fob
rnAb 163H IgG
( a4,CD49d)
rnAb 8A2 Fob
and
rnAb 163H IgG
Figure 6. mAb 8A2does not induce aggregation of U937 cells . Sus-
pension cultures of U937 cellswere incubated with isotype control
mouseIgG (5 ug/ml), mAb 8A2 (5 jg/ml), or 1:100 dilution of the
a4 (CD49d) mAb HP 1/1 for 8 h at 37°C . Similar results were ob-
tained in three separate experiments .
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Figure 5. mAb 8A2 does not
increase surface expression of
u4-subunit (CD49d)of VLA-4
(CD49d)on U937 cells . U937
cells were incubated with iso-
type-matched irrelevant IgG,
mAb8A2Fabfragments alone,
the a4 (CD49d) mAb 163H
alone, or mAb 163H after
pretreatment with mAb 8A2
Fab fragments . Specific bind-
ing ofmAb 163H was assessed
by flaw cytometry as described
in Materials and Methods .
Similar results were obtained
in two additional experiments .
Experiment Basal mAb 8A2-treated
Untreated HUVE
Basal 1 27 .8 t 2.3 33 .9 t 2.6
2 19.9 1 3.0 26.4 1 2.2
3 25.7 1 4.1 33.0 5.2
mAb 60.3 1 9.6 1 1.5 16.6 1 1 .5*
2 6.7 1 0 .8 16.8 1 1 .2*
3 12.7 1 1 .1 20 .3 1 2.6*
mAb 163H 1 19.5 1 2.7 27.4 1 2.6
2 17.3 1 1.9 22 .6 1 3.1
3 17.2 1 0 .8 20.4 1 1 .6
mAb 60.3/163H 1 4.3 1 1 .2 6.2 1 1 .8
2 6.0 0.8 5 .1 1 0.6
3 5.1 1 0.4 4.7 1 0.2
rhTNF-treated HUVE
Basal 1 52 .1 2 .6 54.7 5.3
2 34.2 1 3 .6 34.6 1 5.6
3 32.2 1 5 .4 34.7 1 6.5
mAb 60.3 1 25.5 1 2 .1 39.9 1 4.9*
2 16.6 1 2.8 26.8 1 1 .9*
3 19.9 1 2 .6 27.6 1 6.3
mAb 163H 1 34.8 1 5 .1 46.5 1 1.9
2 31 .2 1 3 .3 31 .5 1 1.8
3 25.3 1 2 .9 26.7 1 3.4
mAb 60.3/163H 1 7.9 1 1 .4 11 .2 1 0.6
2 7.9 1 0.7 7.5 1 0.6
3 8.0 1 1 .1 9.7 1 2.0Isotype
Control
mAb 60.3
(02,C018)
mAb P4C10
(,81,C029)
rnAb 8A2
rnAb 163H
(o4,CD49d)
PBL U937
0.8% untreated and 7.2 f 0.9% with mAb 8A2-treated),
whereas pretreatment of PBL followed by washing produced
stimulation ofbinding comparable to coincubation ofthe an-
tibody (9.6 f 0.6% untreated, 22.1 t 2.1% with mAb 8A2
coincubation and 26.0 f 2 .5 % with mAb 8A2 pretreatment).
mAb842 DoesNotIncreaseSurfaceExpression
ofVLA-4
To determine whether mAb 8A2 modulated VLA-4-depen-
dent binding by altering the surface expression ofVLA-4, we
next determined whether surface expression of VLA-4 was
increased by mAb 8A2. U937 cellswere pretreated with Fab
fragments ofmAb 8A2, followed by saturating concentration
of the a4 (CD49d) mAb 163H. Secondary labeling was per-
formed with FITC-labeled goat antimouse antibody specific
for mouse heavy chain (Fc). On subsequentanalysis by FACS
mAb 8A2 did not induce any alteration of VLA-4 a-subunit
expression (Fig. 5).
mAb 842 Does Not Stimulate HomotypicAdherence
Isolated PBL and U937 were aliquoted into individual wells
in a 96-well plate. mAb 8A2 and the a4 (CD49d) mAbs
HPl/1, HP2/2, and HP2/1 were added at 1:100 dilution ofhy-
bridoma supernatants. Aggregation of PBL and U937 was
observed in wells treated with HPl/1. No aggregation was ob-
served in wells treated with HP2/2, HP2/1, dilutions of mAb
8A2 or with medium alone (Fig. 6).
mAb 842Recognizes the ßl Subunit(CD29)
PBLs, PMN, JY B-lymphoblastoid, cells and U937 cells
were treated with mAbs P4C10 or 4B4 directed against ß,
subunit (CD29), the 02 subunit (CD18) mAb 60.3, mAb
8A2, or isotype-matched control mAbs. After a second incu-
bation with FITC-conjugated goat antimouse antibody, cells
were analyzed by flow cytometry. Fig. 7 demonstrates that
all cells bound the 02 (CD18) mAb 60.3. U937, PBL, and
JY cells expressed the a4 subunit (CD49d) as demonstrated
by binding ofmAb 163H. Peripheral blood lymphocytes and
U937 exhibited quantitatively similar binding of the two 01
(CD29) mAbs and mAb 8A2, whereas PMN and JY cellsdid
not bind the ß, mAbs or mAb 8A2 .
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Detergent lysates from 125I-labeled U937 cells were pre-
cipitated with polyclonal antibody (A108) directed against
a5ß, (CD49e/CD29), the 01 (CD29) mAbs P4C10 or 4B4,
the 02 (CD18) mAb 60.3, or mAb 8A2. Lysates were pre-
cleared by three sequential precipitations with various anti-
bodies and then precipitated with the antibody of interest.
Immunoprecipitates were boiled in sample buffer, subjected
to SDS-PAGE under nonreducing and reducing conditions,
and then autoradiographed. Antibodies directed against ß,
(CD29) precipitated a 115-kD band under nonreducing con-
ditions (Fig. 8 A) that migrated to 140 kD under reducing
conditions (Fig. 8 B). mAb 8A2 precipitated a single band
that comigrated with the band precipitated by ß, antibod-
ies under both reducing and nonreducing conditions. Pre-
clearance of lysate with the ß,-directed antibodies abolished
the precipitation of any band by mAb 8A2 (Fig. 8 B) . Pre-
clearance of lysate with mAb 8A2 ablated precipitation by
ß, (CD29)-specific antibodies. Precipitation with the 02
(CD18) mAb 60.3 was not affected by preclearance with
a5ß,-specific antibody A108 (Fig. 8 B) . Two nonspecific
bands in the 66-97-kD range were observed in all the
precipitations including CD18 mAb 60.3. Similar results
were obtained when lysates were subjected to SDS-PAGE
under nonreducing conditions (data not shown) .
Additional studies were performed using the erythroleu-
kemic cell line K562 which expresses the VLA-5 fibronectin
receptor (a5ß1) but not VLA-4 (a4ß1) (19). Detergent ly-
sates from 'III-labeled K562 cells were precipitated with
polyclonal A108 directed against a5ß1 (CD49e/CD29), the
as (CD49e) mAb PlD6, the ß, (CD29) P4C10, or mAb 8A2.
Analysis by SDS-PAGE and autoradiography revealed that
all four antibodies precipitated two bands under nonreducing
conditions corresponding to as and 01 that comigrated as a
single band under reducing conditions (Fig. 9).
mAb842 Stimulates Binding ofHematopoietic
CellLinesandPBL toPurified Matrix Components
Fibronectin andLaminin
Having established that mAb 8A2 bound to the common 0 1
subunit of VLA (CD29), we next determined whether mAb
8A2 would modulate the affinity of VLA integrin receptors
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Figure 7 . mAb 8A2 binds to
U937 cells and PBL but not to
PMN and JY cells. Binding of
isotype-matched control IgG1 ,
the 02 (CD18) mAb 60.3, the
01 (CD29) mAb P400, the
as (CD49d) mAb 163H, and
mAb 8A2 to JY, U937, PBL,
and PMN was assessed by
flow cytometry as described
in Materials and Methods.
Similar results were obtained
in two additional experiments.Figure 8. mAb 8A2 precipitates a band that co-migrates with a band precipitated by CD29 (0 1) antibodies . Detergent lysates of 121J_
labeled U937 cells were precipitated with polyclonal antibody A108 to VLA-5 fibronectin receptor (ct5ßt) (lane 1), the 0 1 (CD29) mAbs
P4C10 (lane 2) or 4B4 (lane 4), mAb 8A2 (lane 6), or the 02 (CD18) mAb 60 .3 (lane 10) . Precleared samples were precipitated three
times with the designated antibody, then precipitated with the final antibody . Samples were subjected to SDS-PAGE under nonreducing
(A) and reducing (B) conditions and autoradiographed . Similar results were obtained in three experiments. The preclearing antibody and
final precipitating antibody under reduced conditions are shown in the Fig . 8 as follows:
Lane
￿
1 2 3 4
Clearing
antibody - - 8A2 -
Final
mAb A108 P4C10 P4C10 4B4
other than VLA-4 . Binding tohuman fibronectin was evalu-
ated forPBL and U937 cells which express bothVLA-4 and
VLA-5, K562 cells which express VLA-5 (19), and lym-
phoid lines Ramos and Molt-4 which express only VLA-4
(12, 19) . Flow cytometry with alpha chain-specific rnAbs
confirmed the reported selective expression of VLA recep-
tors . Both Molt-4 and Ramos cells expressed significant
amounts ofa4 (CD49d) by flow cytometry analysis . Ramos
cells exhibited no increase in mean cell fluorescence when
treated with the a5 (CD49e) mAb PID6 when compared to
isotype-matched irrelevant mAb, and there was only mini-
mal binding ofmAbPlD6 to Molt-4 cells (mean cell fluores-
cence 47 t 22mAbPID6 comparedto 34 f 18 isotype con-
trol mAb) . mAb 8A2 induced binding to fibronectin in all
cell lines (Fig . 10) with the inhibition of binding by VLA-
alpha chain-directed n Abs dependent upon expressedVLA .
mAb 8A2-stimulated binding ofPBL and U937 cells, which
express VLA-4 and VLA-5, required both the a4 (CD49d)
mAb 163H and the a 5 (CD49e) mAb PID6 to inhibit bind-
ing completely. Stimulated binding ofK562 cells, which ex-
press only a5 (CD49e), was inhibited by the a5 mAb PID6
but not the a4 mAb 163H . Conversely, binding of Molt-4
cells which express predominately a4 (CD49d) was in-
hibited by the a4 mAb 163H but not by the a 5 mAb PID6
Kovach et al . ß, Integrin-induced Leukocyte Adherence
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(Fig . 10) . Binding of Ramos cells which express only a4
(CD49d) demonstrated an identical pattern to Molt-4, with
basal binding of 8.3 f 0.9% andmAb 8A2-induced binding
of 33.3 f 3.4% . mAb PlD6 to a5 (CD49e) did not inhibit
basal or stimulated binding (8.0 t 1.1% and 30.2 t 4.4%,
respectively), while the a 4 mAb 163H inhibited basal and
stimulated binding (0.9 f 0.2% and 0.9 f 0.1%, respec-
tively) .
PBL and U937 cells also express VLA-6 (CD49f/CD29)
by flow cytometry (data not shown) (20), and bound to mu-
rine laminin (Fig . 11) . mAb 8À2-stimulated binding to lami-
nin was inhibited by «6 (CD49f) mAb GoH3 but not a 4
(CD49d) mAb 163H (Fig . 11) . Molt-4, K562, and Ramos
cells do not express VLA-6 by flow cytometry (data not
shown), and did not show significant basal binding or mAb
8A2-stimulated binding to laminin (Fig . 11) .
Discussion
The ß, integrin receptorVLA-4 (a4ß,, CD49d/CD29) func-
tions in the binding of lymphocytes to extracellular matrix
via the CS-1 domain of fibronectin (18, 50), homotypic ag-
gregation oflymphocytes (2, 6), and lymphocyte adherence
to endothelial cells via VCAM-1 (12, 34) . The interaction of
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A108 P4C10 4B4 - A108
8A2 8A2 8A2 8A2 60 .3 60.3Figure 9 mAb 8A2 precipitates bands co-migrating with as and 01
in K562 cells. Detergent lysates of 1151-labeled K562 cells were
precipitated with the VLA-5 fibronectin receptor (a 5ß1 , CD49e/
CD29) polyclonal antibody A108, the CO (CD49e) mAb PID6, the
0, (CD29) mAb P4C10, and mAb 8A2 . Samples were subjected to
7% SDS-PAGE under nonreducing and reducing conditions and au-
toradiographed .
VLA-4 with VCAM-1 is likely an important component of
the adherence of lymphocytes to endothelium at sites of in-
flammation or immune reaction . Modulation of the affinity
ofVLA-4 for VCAM-1 provides one mechanism for the con-
trol of lymphocyte emigration. In this paper we describe a
mAb, 8A2, that rapidly induces VLA-4-dependent binding
of peripheral blood lymphocytes or hematopoietic cells to
VCAM-1-transfected CHO cells or to cytokine-activated
HUVE .
mAb 8A2 was identified by stimulation ofU937 cell bind-
ing to CHO cells transfected with VCAM-1 cDNA but not
ELAM-1 or CD4 cDNA . Binding of U937 cells to VCAM-
1-transfectedCHO cells induced by mAb 8A2 was inhibited
by blocking mAbs to VCAM-1 and as (CD49d) . mAb 8A2
also increased VLA-4-dependentbinding ofPBL toVCAM-
1-transfectedCHO cells and to rhTNF-treated HUVE . mAb
8A2-induced binding was dose-dependent and rapid with
significant stimulation observed at 50 ng/ml and 10 min .
mAb 8A2 activates VLA receptors in addition to VLA-4 .
Treatment ofK562 cells withmAb8A2 increased binding to
fibronectin . K562 cells express only VLA-5, and mAb 8A2-
stimulated binding of K562 to fibronectin was completely
inhibited by an as-subunit (CD49e) mAb . Molt-4 cells ex-
press primarily VLA4 and trace VLA-5 andRamos cells ex-
press only VLA-4 . Binding of Molt-4 and Ramos cells to
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Figure 10. mAb 8A2 stimulates binding of U937, K562, and Molt-4
cells andPBL to purified fibronectin . "Cr-labeled cells were pre-
treated with medium alone or medium containingmAb 8A2 (5 jig/
ml) . Aliquots of "Cr-labeled cells were also treated with the as
(CD49d) mAb 163H, as (CD49e) mAb P1D6 (5 Wg/ml), or both
mAbs . 5'Cr-labeled cells were added to wells containing purified
fibronectin as described in Materials and Methods . Percent adher-
ence was determined aftera 30-min incubation at 37°C. Values rep-
resent means t SEM of triplicate wells in one representative ex-
periment of three separate experiments .
fibronectin was increased by mAb 84,2, and this stimulated
binding was inhibited by the as (CD49d) mAb 163H . Bind-
ing of PBL to fibronectin was also increased by mAb 8A2,
and complete inhibition required both the a s (CD49e) mAb
PID6 and a4 (CD49d) mAb 163H . Additionally, binding of
PBL and U937 cells to laminin was stimulated by mAb 8A2
and inhibited by the a6 (CD49f) mAb GoH3 . These results
show that mAb 8A2 also modulates function of VLA-5 and
VLA-6 as well as VLA-4 .40
30
e
20
40
8 30
° 10
40
30-
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20
40
" 30
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° 10
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Basal 153H GoH3
Figure 11. mAb 8A2 stimulatesbinding of PBL and U937 cells, but
not K562 or Molt-4 cells, to purified murine laminin. 5'Cr-labeled
U937, K562, and Molt-4 cells and PBL were pretreated with me-
dium alone or medium containing mAb 8A2 (5 ug/ml). Aliquots
of each cell type were also treated with the a4 (CD49d) mAb
163H or ab (CD49f) mAb GoH3. 5'Cr-labeled cellswere added to
wells coated with purified laminin as described in Materials and
Methods. Percentadherence was determined aftera 30-min incuba-
tion at 37°C. Values represent means f SEM of triplicate wells in
one representative experiment of three separate experiments.
Our studies indicate that mAb 8A2 recognizes the com-
mon beta-subunit (ß,, CD29) of the VLA-4 integrin. Ra-
dioimmunoprecipitation studies revealed that a band precipi-
tated by mAb 8A2 that comigrated under nonreducing and
reducing conditions with a band precipitated by antibodies
to ß,. Immunodepletion studies demonstrated that preclear-
ance of labeled lysates with antibodies to ß, ablated subse-
quent precipitation by mAb 8A2. Conversely, preclearance
with mAb 8A2 ablated precipitation by antibodies to ß,.
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Furthermore, flow cytometry showed that mAb 8A2 bound
to cell types known to express ß, and that binding of mAb
8A2 was quantitatively similar to that observed with other
ß, (CD29) mAbs (P4C10, 4B4). Conversely, cells lacking
ß, (PMN, JY cells) failed to bind mAb 8A2. The possibil-
ity that mAb 8A2 recognized the a4 subunit (CD49d) of
VLA-4 was excluded by the failure of mAb 8A2 to bind to
JY cells that express a4 but lack ß, . The beta-subunit
which may associate with the a4 subunit in JY cells is un-
known. Additionally, mAb 8A2 precipitated bands from K562
cells which express only VLA-5 (a5ß,) that comigrated with
bands precipitated by antibodies to a5 or a5ß, . These initial
studies do not exclude the possibility that binding of mAb
8A2 may require that the ß, subunit be associated with an
appropriate a-subunit.
mAb 8A2 could increase VLA-4-dependent binding of
U937 or PBL to VCAM-1 by either increasing the surface ex-
pression or the avidity of VLA-4. The fact that monovalent
Fab fragments of mAb 8A2 induced adherence, but did not
increase surface expression of a4 analysis by flow cytome-
try, indicates that increased binding is not due to increased
surface expression of VLA-4 but rather to an increase in
avidity.
mAb 8A2 could modulate the affinity of VLA-4 for
VCAM-1 and fibronectin, VLA-5 for fibronectin, or VLA-6
for laminin either directly by inducing a conformational
change in the receptor upon binding or indirectly by trigger-
ing cell activation. O'Toole et al. (29) have reported that
monovalent Fab fragments of certain N3-specific mAbs
directly stimulated binding of fibrinogen to a,n,ß3 in fixed
platelets, presumably lacking any intracellular signaling
mechanisms, and to detergent-solubilized receptor in the ab-
sence of a membrane microenvironment. Figdor and col-
leagues have described a mAb (NK1-Ll6) that binds to the
a-chain of LFA-1 (CDlla) and stimulates homotypic lym-
phocyte adhesion (14, 22) . The activity ofthis mAb does not
require intracellular signaling, but involves a conformational
change in the LFA-1 receptor increasing its affinity for
ligand.
Numerous studies have shown that the affinity of integrin
receptors for their ligands can be modulated by cell activa-
tion. Stimulation of cells by phorbol esters or physiologic
agonists have been shown to alter binding avidity of ß, (4,
38, 39, 45, 51), 02 (5, 49, 52), and 03 (9, 35, 36) integrin
receptors. Cross-linking of other cell surface receptors by
mAbs has been shown to modulate avidity of 02 (10, 48) . In
particular, mAbs to the a-subunit of VLA-4 (CD49d) have
been shown to induce VLA-4-dependent homotypic lym-
phocyte adhesion (2, 6) by a mechanism requiring energy
and intact cytoskeleton (6) . Recently, binding of a mAb to
the ß,-subunit (CD29) has been reported to transduce a sig-
nal to T cellsresulting in elevation ofcAMP (17), and neuron
adhesion to laminin and collagen (27) .
Our initial studies do not determine whether mAb 8A2 acts
directly or indirectly. Monovalent Fab fragments of mAb
8A2 were active indicating that cross-linking of the receptor
is not required. mAb 8A2-induced binding of PBL to
VCAM-1 required a metabolically active cell, since pretreat-
ment with sodium azide and deoxyglucose prevented the in-
crease in binding. These latter results suggest that mAb 8A2
may increase the avidity of VLA-4 by an indirect mechanism
requiring active cell metabolism. More detailed studies,
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Mile r- .- .1 Ihowever, are required to determine the precise mechanism
by which mAb ßA2 alters the affinity ofVLA-4 and other leu-
kocyte ß, integrins.
In summary, we have described a mAb to the ß, subunit
that rapidly stimulates the binding ofVLA-4 to VCAM-1 and
fibronectin, as well as VLA-5 to fibronectin and VLA-6 to
laminin. This mAb may proveto be an important tool in un-
derstanding the regulation of leukocyte ß, integrin function.
We thank Dr. Perumal Thiagarajan for his valuable discussions, sugges-
tions, and technical assistance; and Drs. Patrick Beatty, Roy Lobb,
Christopher Benjamin, Margaret Rosa, Barbara Wallner, Michael Galla-
tin, Charles Hart, Karl E. Hellstrom, Francisco Sanchez-Madrid,
Elizabeth Wayner, Taco Kuijpers, and Arnoud Sonnenberg who provided
valuable reagents.
This work was supported by U.S. Public Health Service grants HL-
18645 and HL-07093-16. J. Harlan is the recipient ofan Established inves-
tigatorship of the American Heart Association.
Received for publication 2 May 1991 and in revised form 13 September
1991 .
References
1. Beatty, P. G., l. A. Ledbetter, P. J. Martin, T. H . Price, and J. A. Hansen.
1983 . Definitionofa common leukocyte cell-surface antigen (GP95-150)
associated with diverse cell-mediated immune functions. J. Immunol.
131 :2913-2919.
2. Bednarczk, J. L., and B. W. McIntyre. 1990. A monoclonal antibody to
VLA-4 a-chain (CDw49d) induces homotypic lymphocyte aggregation.
J. Immunol. 144:777-784.
3. Benjamin, C., I. Douglas, G. Chi-Rosso, S. Luhowskyj, M. Rosa, B. New-
man, L. Osborn, C . Vassallo, C. Hession, S. Goelz, K. McCarthy, and
R. Lobb. 1990. A blocking monoclonal antibody to endothelial-leukocyte
adhesion molecule-1 (ELAM-1). Biochem. Biophys. Res. Commun. 171 :
348-353.
4. Brown, P. J. 1988. Phorbol ester stimulation of fibronectin-mediated cell
adhesion. Biochem. Biophys. Res. Commun. 155:603-607.
5. Buyon, J. P., S. G. Slade, J. Reibman, S. B. Abramson, M. R. Philips,
G. Weissman, and R. Winchester. 1990. Constitutive and induced phos-
phorylation of the a- and 0-chains ofthe CDIl/CD181eukocyte integrin
family. J. Immunol. 144:191-197.
6. Campanero, M. R., R. Pulido, M . A. Ursa, M. Rodriguez-Maya, M. O.
de Landazuri, and F. Sanchez-Madrid. 1990. An alternative leukocyte
homotypicadhesion mechanism, LFA-I/ICAM-1-independent, triggered
through the human VLA-4 integrin. J. Cell Biol. 110:2157-2165 .
7. Carlos, T. M., B. R. Schwartz, N. L. Kovach, E. Yee, M. Rosa, L. Os-
born, G. Chi-Rosso, B. Newman, R. Lobb, andJ. M. Harlan. 1990. Vas-
cular cell adhesion molecule-1 mediates lymphocyte adherence to cyto-
kine-activated cultured human endothelial cells. Blood. 76:965-970.
8. Carter, W. G., E. A. Wayner, T. S. Bouchard, and P. Kant. 1990. The
role of integrins a2ß, and a3ß, in cell-cell and cell-substrate adhesion of
human epidermal cells. J. Cell Biol. 110:1387-1404.
9. Coller, B. S. 1985. A new murine monoclonal antibody reports an ac-
tivation-dependent change in the conformation and/or microenvironment
oftheplatelet glycoprotein Ilb-IIIa complex.J. Clin. Invest. 76:101-109.
10. Dustin, M. L., andT. A. Springer. 1989. T-cell receptorcross-linking tran-
siently stimulates adhesiveness through LFA-1 . Nature (fond.). 341:
619-624.
11 . Dustin, M. L., R. Rothlein, A . K. Bhan, C. A. Dinarella, and T. A.
Springer. 1986. Induction by IL-1 and interferon-y: tissue distribution,
biochemistry, and function of a natural adherence molecule (ICAM-1).
J. Immunol. 137:245-254.
12. Elices, M. J., L. Osborn, Y. Takada, C. Crouse, S. Luhowsky, M . E.
Hemler, and R. R. Lobb. 1990. VCAM-1 onactivated endothelium inter-
acts with the leukocyte integrin VLA-4 ata site distinct from the VLA-4/
fibronectin binding site. Cell. 60:577-584.
13. Ey, P. L., S. J. Prouse, and C. R. Jenkin. 1978. Isolation of pure IgG1,
IgG2a, and IgG2b immunoglobulins from mouse serum using protein
A-sepharose. Biochemistry. 15 :429-436.
14. Figdor, C. G., Y. van Kooyk, and G. D. Keizer. 1990. On the mode of
action of LFA-1 . Immunol. Today. 11:277-280.
15. Galfre, G., S. C. Howe, C. Milstein, G. W. Butcher, and J. C. Howard.
1977. Antibodies to major histocompatability antigens produced by hy-
brid cell lines. Nature (Load.). 266:550-552.
16. Graber, N., T. V. Gopal, D. Wilson, L. D. Beall, T. Polte, and W. New-
man. 1990. T cells bind to cytokine-activated endothelial cells via a
novel, inducible sialoglycoprotein and endothelial leukocyte adhesion
The Journal of Cell Biology, Volume 116, 1992
molecule-1 . J. Immunol. 145:819-830.
17. Groux, H., S. Huet, H. Valentin, D. Pham, and A. Bernard. 1989. Sup-
pressor effects and cyclic AMP accumulation by the CD29 molecule of
CD4' lymphocytes. Nature (Land.). 339:152-154.
18. Guan, J.-L., and R. O. Hynes. 1990. Lymphoid cells recognize an alter-
nately spliced segment of fibronectin via the integrin receptor a4ß,.
Cell. 60:53-61 .
19. Hemler, M. E., C. Haung, and L. Schwartz. 1987. The VLA protein fam-
ily. J. Biol. Chem. 262:3300-3309.
20. Hemler, M. E., C. Crouse, and A. Sonnenberg. 1989. Association of the
VLA a6 subunit with a novel protein. J. Biol. Chem. 264:6529-6535.
21 . Hoogenraad, N. J., and C. J. Wraight. 1986. The effect ofpristane on as-
cites tumor formation and monoclonal antibody production. Methods En-
zymol. 121 :375-381.
22. Keizer, G. D., W. Visser, M. Vliem, and C. G. Figdor. 1988. A monoclo-
nal antibody (NKl-L16) directed against aunique epitope on the a-chain
ofhumanleukocyte function-associated antigen 1 induces homotypic cell-
cell interactions. J. Immunol. 140:1393-1400.
23 . Lane, T. A., G. E. Lamkin, and E. Wancewicz. 1989. Modulation of en-
dothelial cell expression of intercellular adhesion molecule 1 by protein
kinase C activation. Biochem. Biophys. Res. Commun. 161:945-952.
24. Maciag, T., J. Cerundolo, S. Iisley, P. R. Kelley, and R. Forland. 1979.
An endothelial cell growth factor from bovine hypothalamus: identifica-
tion and partial characterization. Proc. Natl. Acad. Sci. USA. 76:5674-
5678.
25 . Marlin, S. D., and T. A. Springer. 1987. Purified intercellular adhesion
molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated
antigen-1 (LFA-1). Cell. 51 :813-819.
26. Masinovsky, B., D. Urdal, and W. M. Gallatin. 1990. IL-4 acts synergisti-
cally with IL-lßto promote lymphocyte adhesion to microvascular endo-
thelium by induction of vascular cell adhesion molecule-1 . J. Immunol.
145:2826-2895.
27. Neugebauer, K. M., and L. F. Reichardt. 1991 . Cell-surface regulation of
$,-integrin activity on developing retinal neurons. Nature (Land.). 350:
68-71.
28. Osborn, L., C. Hession, R. Tizard, C. Vassallo, S. Luhowskyj, G. Chi-
Rosso, and R. Lobb. 1989. Direct expression cloning ofvascular cell ad-
hesion molecule-1, a cytokine-induced endothelial protein that binds to
lymphocytes. Cell. 59:1203-1211.
29. OToole, E., J. C. Loftus, X. Du, A. A. Glass, Z. M. Ruggeri, S. J. Shattil,
E. F. Plow, and M. H. Ginsberg. 1990. Affinity modulation of the
a  .ß3 integrin (platelet GPIIb-IIIa) is an intrinsic property ofthe recep-
tor. Cell Reg. 1 :883-893.
30. Pober, J. S., M . A. Gimbrome Jr., L. A. Lapierre, D. L. Mendrick, W.
Fiers, R. Rothlein, and T. A. Springer. 1986. Overlapping patterns of
activationofhuman endothelial cells by interleukin-1, tumor necrosis fac-
tor, and immune interferon. J. Immunol. 137:1893-1896.
31 . Pohlman, T. H., K. A. Stanness, P. G. Beatty, H. D. Ochs, and J. M.
Harlan. 1986. An endothelial cell surface factor(s) induced in vitro by
lipopolysaccharide,interleukin 1, and tumor necrosis factor-a increases
neutrophil adherence by a CDwl8-dependent mechanism. J. Immunol.
136:4548-4552 .
32. Rice, G. E., J. M. Munro, andM. P. Bevilacqua. 1990. Inducible cell adhe-
sion molecule 110 (INCAM-110) is an endothelial receptor for lympho-
cytes. J. Exp. Med. 171:1369-1374.
33. Sanchez-Madrid, F., M. O. De Landazuri, G. Morago, M. Cebrian, A.
Acevedo, and C. Bernabeu. 1986. VLA-3 : A novel polypeptide associa-
tion within the VLA molecular complex: cell distribution and biochemi-
cal characterization. Eur. J. Immunol. 16:1343-1349.
34. Schwartz, B. R., E. A. Wayner, T. M. Carlos, H. D. Ochs, and J. M .
Harlan. 1990. Identification of surface proteins mediating adherence of
CDII/CD18-deficient lymphoblastoid cells to cultured human endo-
thelium. J. Clin. Invest. 85:2019-2022.
35 . Shattil, S. J., and L. F. Brass. 1987. Induction of the fibrinogen receptor
on human platelets by intracellular mediators. J. Biol. Chem. 262 :992-
1000.
36. Shattil, S. J., J. A. Hoxie, M. Cunningham, and L. F. Brass. 1985 .
Changes in the platelet membrane glycoprotein Ilb-IIIa complex during
platelet activation. J. Biol. Chem. 260:11107-11114.
37. Shimizu, S., and S. Shaw. 1991 . Lymphocyte interactions with extracellu-
lar matrix. FASEB (Fed. Am. Soc. Exp. Biol.) J. 5:2292-2299.
38. Shimizu, S., G. A. Van Seventer, K. J. Morgan, and S. Shaw. 1990. Regu-
lated expression and binding of three VLA (ß,) integrin receptors on T
cells. Nature (Land.). 345:250-253.
39. Shimizu, S., W. Newman, T. V. Gopal, K. J. Horgan, N. Graber, L. D.
Beall, G. A . van Seventer, and S. Shaw. 1991 . Fourmolecular pathways
of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and
ELAM-1 and changes in pathway hierarchy under different activation
conditions. J. Cell Biol. 113:1203-1212.
40. Simmons, D., M. W. Makgoba, and B. Seed. 1988. ICAM, an adhesion
ligand of LFA-1, is homologous to the neural cell adhesion molecule
NCAM. Nature (Land.). 331 :624-627 .
41 . Sonnenberg, A., H. Janssen, F. Hogervorst, J. Calafat, and J. Hilgers.
1987. A complex of platelet glycoproteins le and Ha identified by a rat
monoclonal antibody. J. Biol. Chem. 262:10376-10383.
50842. Sonnenberg, A., P. W . Modderman, and F. Hogervorst. 1988. Laminin
receptor on platelets is the integrin VLA-6. Nature (Gond.). 336:487-
489.
43. Staunton, D. E., S. D. Marlin, C. Stratowa, M . L. Dustin, and T. A.
Springer. 1988. Primar y structure of intercellular adhesion molecule 1
(ICAM-1) demonstrates interaction between members of the immuno-
globulin and integrin supergene families. Cell. 52:925-933.
44. Staunton, D. E., M. L. Dustin, and T. A. Springer. 1989. Functional
cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to
ICAM-1 . Nature (Lond.). 339:61-64.
45. Symington, B . E., F. W. Symington, and L. R. Rohrshneider. 1989. Phor-
bol ester induces increased expression, altered glycosylation, and re-
duced adhesion of K562 erythroleukemia cell fibronectin receptors. J.
Biol. Chem. 264:13258-13266.
46. Thornhill, M. H., S. M. Wellicome, D . L. Mahiouz, J. S. S. Lanchbury,
U. Kyan-Aung, and D. O. Haskard. 1991 . Tumor necrosis factor com-
bines with IL-4 or IFN-gamma to selectively enhance endothelial cell
adhesiveness for T cells: the contribution of vascular cell adhesion
molecule-l-dependent and -independent binding mechanisms. J. Im-
munol. 146:592-598.
Kovach et al. ,Q, Integrin-induced Leukocyte Adherence
47. Thorton, S. C., N. Mueller, and E. M. Levine . 1983. Huma n endothelial
cells: use of heparin in cloning and long-term serial culture. Science
(Wash. DC). 222:623-625.
48. van Kooyk, Y., P. van de Wiel-van Kemenade, P. Weder, T. W. Kuijpers,
and C . G., Figdor. 1989. Enhancement ofLFA-1-mediated cell adhesion
by triggering through CD2 or CD3 on T lymphocytes. Nature (Lond.).
342:811-813.
49. Vedder, N. B., and J. M. Harlan. 1988. Increased surface expression of
CDIIb/CD18 (Mac-1) is not required for stimulated neutrophil adher-
ence to cultured endothelium. J. Clin. Invest. 81 :676-682.
50. Wayner, E. A., A. Garcia-Pardo, M. J. Humphries, J. A. McDonald, and
W. G. Carter. 1989. Identification and characterization ofthe T lympho-
cyte adhesion receptor for an alternative cell attachment domain (CS-1)
in plasma fibronectin. J. Cell Biol. 109:1321-1330.
51 . Wilkins, J. A., D. Stupack, S. Stewart, and S. Caxia. 1991. ß, integrin-
mediated lymphocyte adherence to extracellular matrix is enhanced by
phorbol ester treatment. Eur. J. Immunol. 21 :517-522.
52. Wright, S. D., and C. B. Meyer. 1986. Phorbol esters cause sequentialacti-
vation and deactivation ofcomplement receptors on polymorphonuclear
leukocytes. J. Immunol. 136:1759-1764.
509